Galapagos’ JAK1 Inhibitor Is One To Contend With Just today, Galapagos announced a major partnership with Abbott to develop its JAK1 specific inhibitor for the treatment of rheumatoid arthritis. This Belgium based biotech snagged a lucrative deal with $150 million in upfront payments. Upon the completion of Phase II studies, Abbott has the option to […]
MYRX – Myrexis update following earnings release
Myrexis $MYRX (spun off from Myriad Genetics $MYGN and formerly known as Myriad Phamaceuticals), announced fiscal second quarter 2012 earnings on February 9, 2012. A very brief webcast was held, though there was no question and answer session (it was not clear whether there was no one on the line to ask a question, or […]
PCYC – Pharmacyclics: Initiate Coverage
Overview: Pharmacyclics is a mid-stage drug discovery company with several compounds in clinical development. The company’s major focus is a Bruton’s Tyrosine Kinase (Btk) inhibitor for non-Hodgkin’s Lymphoma (NHL) and Multiple Myeloma, PCI-32765, now in Phase II trials. It is in a broad program in testing against the major NHL subtypes both as monotherapy and […]
INCY – Initiate Coverage on Incyte
Incyte Pharmaceuticals (INCY) Initiating Coverage: Incyte Pharmaceuticals is a small biotech company focused on developing treatments for cancer and inflammatory disorders. Lead compound Ruxolitinib (INCB18424) is awaiting FDA approval for the treatment of Myelofibrosis (MF) with an expected decision date on December 3rd. Ruxolitinib is also recruiting patients in a global Phase III study for […]
